Loss of USP22 had no effect on ERBB2 RNA or protein expression driven by the CMV promoter in MCF10A cells or on endogenous ERBB2 protein expression in two HER2-positive breast cancer cell lines, SKBR3 and HCC1954. This evidence concerns the gene ERBB2 and breast carcinoma.